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Abstract 
We have investigated whether the mutation rate varies between genes and 
sites using de novo mutations (DNMs) from three genes associated with 
Mendelian diseases. We show that the relative frequency of mutations at CpG 
dinucleotides relative to non-CpG sites varies between genes and relative to 
the genomic average. In particular we show that the rate of transition mutation 
at CpG sites relative to the rate of non-CpG transversion is substantially 
higher in our the disease genes than amongst DNMs in general; the rate of 
CpG transition can be several hundred-fold greater than the rate of non-CpG 
transversion. We also show that the mutation rate varies significantly between 
sites of a particular mutational type, such as non-CpG transversion, within a 
gene. We estimate that for all categories of sites, except CpG transitions, 
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there is at least a 30-fold difference in the mutation rate between the 10% of 
sites with the highest and lowest mutation rates. However, our best estimate 
is that the mutation rate varies by several hundred-fold variation. We suggest 
that the presence of hypermutable sites may be one reason certain genes are 
associated with disease. 
 
 
Introduction. 
There is evidence that the mutation rate varies substantially across the human 
genome in the germ-line from studies of de novo mutations (DNMs) (Francioli, 
et al., 2015; Michaelson, et al., 2012) and from comparative genomics 
(reviewed in (Hodgkinson and Eyre-Walker, 2011)). Although this occurs at a 
number of different scales the most dramatic variation is seen at the single 
nucleotide level (Hodgkinson and Eyre-Walker, 2011). In part this variation is 
due to context - the identity of the nucleotides surrounding a site (Bulmer, 
1986; Cooper and Krawczak, 1990; Gojobori, et al., 1982; Hwang and Green, 
2004; Nachman and Crowell, 2000). The most well known example of a 
context effect is that of CpGs; C followed by G is often methylated in 
mammals, and methylated cytosine undergoes a high rate of deamination to 
generate T (Bulmer, 1986; Cooper and Krawczak, 1990; Coulondre, et al., 
1978; Gojobori, et al., 1982; Hwang and Green, 2004; Nachman and Crowell, 
2000). It has been estimated that CpGs undergo rates of mutation 10-15 fold 
higher than other sites in the human genome (Hwang and Green, 2004; 
Nachman and Crowell, 2000) and generate ~20% of all mutations (Fryxell and 
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Moon, 2005). There are also other context effects, but these lead to variation 
in the mutation rate of only 2 to 3-fold (Hwang and Green, 2004).  
 
In addition to variation associated with context, there also appears to be 
variation at the single nucleotide level that does not depend upon the identity 
of the adjacent nucleotides, at least not in a simple manner, variation that has 
been termed cryptic (Hodgkinson, et al., 2009). The evidence for this variation 
initially came from the observation that there is at least a 50% excess of sites 
in which humans and chimpanzees share a single nucleotide polymorphism 
(SNP), even when the influence of context on the mutation rate is taken into 
account (Hodgkinson, et al., 2009). Such an excess could be due to 
sequencing error, assembly error of paralogous duplications or ancestral 
polymorphism. However, several lines of evidence suggest that these 
explanations do not explain the excess of coincident SNPs. First, the 
distribution of allele frequencies amongst coincident SNPs is identical to non-
coincident SNPs (Johnson and Hellmann, 2011); if coincident SNPs were due 
to assembly errors or ancestral polymorphisms we would expect them to be 
more frequent in the population than other SNPs. Second, sequencing 
coverage is no greater at coincident SNPs than other sites (Johnson and 
Hellmann, 2011). And third, there is also an excess of coincident SNPs 
between human and macaque (Hodgkinson, et al., 2009), two species which 
are very unlikely to share ancestral polymorphisms. There is also an excess 
of sites with substitutions in two independent pairs of primate species 
(Johnson and Hellmann, 2011). These lines of evidence therefore suggest 
that the excess of coincident SNPs most likely arises from variation in the 
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mutation rate that is not associated with context, at least not sequence 
contexts that are close to the site in question. It has been estimated that 
cryptic variation may generate more variance in the mutation rate than simple 
contexts, such as the CpG effect (Hodgkinson, et al., 2009).  
 
Although, variation in the mutation rate is most conspicuous at a single 
nucleotide scale it has also been known for sometime that the mutation varies 
at larger scales in the human genome (Matassi, et al., 1999; Michaelson, et 
al., 2012; Spencer, et al., 2006). The scale of this variation remains poorly 
characterised but a recent analysis of where DNMs occur suggest that the 
variation is probably at a scale of 10,000s of base pairs (Michaelson, et al., 
2012). The variation in the rate of CpG and non-CpG mutations appears to be 
at least partly independent, because the variation correlates to different 
genomic variables (Tyekucheva, et al., 2008), but no systematic analysis of 
the relative rates of CpG and non-CpG mutation has been performed to our 
knowledge. 
 
Here we investigate two aspects of variation in the mutation rate. First, does 
the relative frequency of transition and transversion mutations at CpG and 
non-CpG sites differ between genes, and second, is there variation in the 
mutation rate for transition and transversion mutations within CpG and non-
CpG sites (e.g. does the rate of transition mutation differ between CpG sites 
within a single gene). We address these questions using a dataset of de novo 
mutations (DNMs) that have been discovered during clinical screening in 
three genes associated with Mendelian diseases. In each case the DNMs 
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were discovered in an unbiased manner – the causative gene was sequenced 
in a patient with the disease and their parents who did not have the disease.  
 
Methods 
Data 
DNMs were discovered as part of routine clinical screening for individuals 
suffering from bi-lateral retinoblastoma, neurofibromatosis type I and Rett’s 
syndrome; these diseases are caused by mutations in RB1, NF1 and MECP2 
respectively. All data were collected after Ethics committee approval at each 
of the institutions involved. The MECP2 data were gathered from RettBASE, 
International Rett Syndrome Foundation MECP2 Variation Database 
(http://mecp2.chw.edu.au), a curated database for MECP2 variants from 
research and clinical laboratories {Christodoulou, 2003 #1369}. Variants 
included in this study were limited to those for which parental testing had been 
carried out, with both parents tested for female patients, or maternal testing 
for male patients, since the gene is X-linked. Only variants from studies in 
which exons 2-4 had been sequenced were included, and our analysis was 
restricted to this part of the gene. The NF1 data were gathered from the NF1 
LOVD database 
(https://grenada.lumc.nl/LOVD2/mendelian_genes/home.php?select_db=NF1). 
Both parents were tested for the pathogenic mutation and the father was 
tested for paternity. We only included studies in which all exons had been 
sequenced in transcript variant 2, this differs from transcript vatiant 1 in 
missing exon 23a. The RB1 data came from three laboratories. Mutations 
were identified using a number of approaches including sequencing, single 
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strand conformational polymorphism, heteroduplex analysis and high 
resolution melt analysis. Mutations were confirmed in each case by direct 
sequencing. There is alternative start codon in RB1 in the first exon {Sanchez-
Sanchez, 2007 #1372} and so exon 1 was ignored in the analysis.  Both 
parents were tested for all RB1 variants. Some of the RB1 data has been 
previously published in {Price, 2014 #1368}. The transcript numbering that we 
use is from NM_004992.3 for MECP2, NM_000267 for NF1 and 
NM_000321.2 for RB1. We focus our analysis on nonsense mutations since 
nonsense mutations are more likely to have consistent phenotypic effects 
(see results section for further discussion). 
 
Testing for mutation rate variation between genes 
We performed to two tests of mutational rate heterogeneity. First we tested 
whether the relative rates of CpG transitions, CpG transversions, non-CpG 
transitions and non-CpG transversions were significantly different between 
genes and between the genes and the background rate. To do this we 
performed a chisquare goodness-of-fit test, in which we calculated the 
expected number of CpG transitions and transversions, and non-CpG 
tranistions and transversions, assuming that the ratios between the various 
mutational types were the same in the two genes, by finding the parameters 
of a simple model which minmised the chi-square statistic. We assumed that 
each gene has its own “mutation rate”, which reflects both the intrinsic 
mutation rate and the probability that the mutation comes to clinical attention; 
let this be μi. If we assume that the relative rates of the different mutation 
categories are the same in two genes then without loss of generality we can 
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let the rate of non-CpG transversions rate be μi and the rates of CpG 
transition, CpG transversion and non-CpG transition be μi rcts, μi rctv, and μi rnts, 
where rcts, rctv and rnts are shared between the two genes. To test whether the 
patterns of mutation are the same we find the values of μi, rcts, rctv and rnts that 
minmise the chi-square value, comparing the observed and expected values. 
Having found the parameters that minimise the chi-square value we 
performed a goodness of fit test using the ch-square value with 3 degrees of 
freedom (because we have eight observations, the number of CpG and non-
CpG transitions and transversions for each gene, and we have estimated 5 
parameters). 
 
Testing for mutation rate variation within genes 
Second, we tested whether the rate of mutation varied within a mutational 
category (e.g. CpG transitions). If the rate of mutation is the same across all 
sites of a particular type then DNMs should be randomly distributed across 
those sites. To test whether DNMs tend to recur at sites more often than by 
chance we generated the expected number of sites hit recurrently by DNMs 
by randomly distributing the observed number of DNMs of the required type 
(e.g. CpG transitions) across the sites of that type that could generate a 
nonsense mutation. For each randomized dataset we tabulated the number of 
sites a site was hit zero, once, twice…etc by a DNM. By repeating this 
randomization 10,000 times we derived the expected distribution of DNMs (i.e. 
the number of times a site is expected to have been hit by one, two…etc 
DNMs). We compared the observed to the expected using a chi-square test. 
However, the test statistic is unlikely to be chi-square distributed because 
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some of the expected values can be very small, We therefore empirically 
determined the distribution of the chi-square statistic by calculating the chi-
square statistic for each simulated dataset using the expected values 
estimated across all simulated datasets (as we did for the observed data). We 
then compared the observed chi-square statistic to this distribution. The p-
value was the proportion of simulated datasets that had a chi-square value 
greater than observed chi-square value plus half the simulated datasets that 
had an identical chi-square value; this latter condition prevents the test being 
overly conservative when there are few DNMs. We performed simulations to 
check that this method did not generate excessive levels of type I error. For a 
given number of DNMs and sites we randomly allocated DNMs across sites 
and tabulated the number of sites that had been hit 0,1,2…etc times. We then 
performed the analysis as though this was real data, and repeated this 1000 
times for a given combination of sites and DNMs. Simulations confirm that it 
does not increase the level of type I error, although it can decrease it when 
there are very few DNMs.  
 
To combine probabilities from the heterogeneity tests we used the unweighted 
z-method (Whitlock, 2005); in this method we find the z-value of the a normal 
distribution, with a mean of zero and variance of one, that would yield the 
corresponding p-value. These z-values can be added to yield a z-value with 
an expected mean of zero and a variance equal to the number of tests that 
have been combined. The overall p-value is then obtained by converting the 
combined z-value into a p-value. We set p-values in which no simulated data 
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had a greater chi-square value to 0.0001, and no simulated data had a 
smaller chi-square to 0.9999. 
 
Parameter estimation 
We estimated the variation in the mutation rate within a mutational category 
as follows. Let us assume that the mutation rate at a site is 
m a
 where 
m
 is 
the mean mutation rate and  is a deviation from the mean that is taken from 
some distribution D(a ), which has a mean of 1; in our analysis we assume 
that D(a ; b ) is a gamma distribution with a shape parameter . The number of 
mutations at a site can be modelled as a Poisson process because mutations 
are rare events, and hence the number of mutations at a site is Poisson 
distributed. The probability of observing x mutations at a site is therefore 
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which is the negative binomial distribution, where u=μk and k is a parameter 
proportional to the chance of observing a DNM; this is dependent upon the 
incidence and interest in the disease. The number of sites with x mutations is 
multinomially distributed and hence the  likelihood of observing nx sites with x 
mutations is 
 
L(u, b ) = n! G(x;u, b )
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Õ
       (2) 
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where n is the total number of sites. We found the maximum likelihood values 
of the distribution using the Nelder-Mead algorithm as implemented in the 
NMaxmize function in Mathematica. The model above is described for a 
single mutational category in a single gene. However, it is straightforward to 
expand the analysis across multiple mutational categories and genes. In each 
analysis each mutational category in each gene is allowed its own u 
parameter reflecting the fact that the chance of observing a mutation varies 
between genes, and that the rate of mutation varies between mutational 
categories. Confidence intervals on parameters were derived from the 
likelihood surface – i.e. by finding the parameter values that decreased the 
log-likelihood by 2 units. 
 
 
Results 
Data 
We have analysed DNMs in three genes that are associated with Mendelian 
disease. The genes are RB1, mutations in which cause retinoblastoma; we 
only consider mutations causing bilateral retinoblastoma since this disease is 
almost exclusively caused by a de novo germ-line mutation, whereas 
unilateral retinoblastoma is usually caused by somatic mutations. The second 
gene we consider is NF1, mutations in which cause neurofibromatosis type I. 
And the third gene is MECP2, mutations in which cause Rett’s syndrome.  
 
It is critical to our analysis that all mutations in a gene have similar penetrance, 
otherwise any apparent variation in the mutation rate might be due to variation 
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in penetrance (i.e. a site with multiple recurrent DNMs might have a high 
mutation rate or the mutation might be partly penetrant). As a consequence 
we only consider nonsense mutations and in RB1 and NF1 we only consider 
sites at which nonsense mutations are predicted to be caught by nonsense 
mediated decay (NMD). Furthermore, in RB1 we ignore data from the first 
exon because mutations in the first exon may display variable levels of 
penetrance due to alternative transaltion initiation sites {Sanchez-Sanchez, 
2007 #1372}. All the nonsense mutations we consider in RB1 and NF1 should 
therefore have the same probability of being detected. The analysis of 
MECP2 is more complex because the vast majority of sites that could 
generate a nonsense mutation are in the last exon and hence would not be 
caught by NMD; hence some nonsense mutations, particularly those towards 
the end of the gene could be less penetrant than those earlier in the gene. 
Furthermore, it is possible that nonsense mutations in the second and third 
exons (first and second coding exons) are lethal and therefore not routinely 
observed. Figure 1 shows the distribution of DNMs along the MECP2 gene. It 
is conspicuous that almost all pathogenic mutations occur between the start of 
the final exon and the end of the transcription repression domain. As a 
consequence we analysed two datasets for MECP2 – all sites at which a 
nonsense mutations could occur, and all sites at which nonsense mutations 
could occur between the first and last sites that have multiple DNMs (sites 
423 to 889 inclusive). Reducing the dataset in this manner does not alter the 
relative rates of mutation greatly, but it does reduce the evidence for 
heterogeneity within mutational categories (see below); this reduced dataset 
can therefore be considered a conservative dataset. 
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Table 1 gives the number of DNMs in each of four mutation categories, 
transitions and transversions at CpG sites, and transitions and transversions 
at non-CpG sites, and Table S1 gives the number of sites hit by 0,1, 2…etc 
DNMs. We divided the data in this way because there are large differences in 
the rate of mutation of these mutational types (reviewed in (Hodgkinson and 
Eyre-Walker, 2011). For each of our genes we have large numbers of 
nonsense DNMs. These are dominated by CpG transitions but we have 
substantial numbers of non-CpG transitions and transversions. 
 
 
Heterogeneity between genes 
It is of interest to know whether the frequencies of different types of mutation 
vary substantially between genes. Unfortunately, because of the way in which 
our data have been sampled we cannot answer this question directly – the 
rate at which DNMs are detected in our genes depends upon the frequency of 
the disease, the severity of phenotype and the interest of clinicians. However, 
we can compare the relative frequency of different types of mutation between 
genes and compare those between genes and to the genomic average. We 
test for differences between genes, and between genes and the genomic 
average using a chi-square goodness of fit test, fitting a model in which we 
assume the relative rates of mutation in the four mutational categories are the 
same in the two genes (or genes and genome) (see the Materials and 
Methods section). 
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Two recent studies have obtained substantial numbers of DNMs from the 
complete genome sequencing of trios (Kong, et al., 2012; Michaelson, et al., 
2012). Surprisingly the relative frequencies of the four mutation types differ 
significantly between these studies (Table 2)(Chi-square goodness of fit test p 
= 0.045). The difference seems to be largely a consequence of a higher 
relative rate of CpG transitions in the data of Kong et al. (Kong, et al., 2012) 
compared to the data of Michaelson et al. (Michaelson, et al., 2012) (28x the 
rate of non-CpG transversions versus 19x) (Table 2). The reason for this 
discrepancy is not clear; it may be due to different ages amongst the two 
cohorts, or different biases in the sequencing methods, as other analyses 
seem to suggest (Eyre-Walker and Eyre-Walker, 2014). 
 
However, more striking than the difference between the two trio datasets are 
the differences in the relative rates of mutation between these datasets and 
the three genes for which we have DNMs (Table 2); each of the disease 
genes shows higher rates of mutation relative to the rate of non-CpG 
transversion than trio datasets. The most dramatic difference is the relative 
rate of CpG transition mutation in the MECP2 gene where the mutation rate is 
estimated to be over 240x higher than the rate of non-CpG transversion (640x 
for the complete MECP2 dataset and 236x for the restricted dataset). Pairwise 
comparisons show that the patterns of mutation are highly significantly 
different between MECP2 and the other two genes (Chi-square goodness of 
fit tests: p<0.001 in both cases), but not between RB1 and NF1. The patterns 
are also highly significantly different between each of the three genes and 
both the datasets of Kong et al. and Michaelson et al (Chi-square goodness of 
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fit tests: p<0.0001). Unfortunately, it is not possible to say from these data 
whether the large relative rates are due to a low rate of mutation at non-CpG 
sites or a high rate at CpG sites.  
 
Heterogeneity within genes 
The analyses above show that the relative frequency of different types of 
mutation varies between genes. We can also test whether the rate of mutation 
within each of these mutational types varies between sites within a gene. 
Using a chi-square test of heterogeneity (deriving the null distribution by 
randomisation) we find highly significant evidence of heterogeneity over the 
entire dataset whether we consider all sites in the MECP2 gene or the 
restricted MECP2 dataset (p < 10-5). Surprisingly we significant homogeneity, 
not heterogeneity, for CpG transitions sites in the RB1 gene (i.e. mutations 
are more evenly distributed between sites than one would expect by chance 
alone). The data for this gene comes from three different labs. None of these 
datasets shows this excessive homogeneity individually and in fact the 
dataset from Barts Hospital shows marginally significant evidence of 
heterogeneity (p=0.081) (Table S2). The datasets are not significantly 
different to each other (chi-square = 23.6, df = 20, p = 0.26) (Table S3). It 
therefore remains unclear why the combination of the three datasets leads to 
significant homogeneity.  
 
The strongest evidence for heterogeneity comes from non-CpG tranversions 
in the MECP2 gene. In the restricted dataset there are 38 sites at which a 
non-CpG transversion will generate a nonsense mutation and there are 10 
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DNMs that have occurred at these sites. However, 6 of the DNMs have 
occurred at one site (site 423); all of these are C>G changes even though a 
C>A would also generate a stop codon. 
 
Using the heterogeneity analysis we can identify 3 sites that have mutation 
rates that are significantly above background levels (Table 4). The mutation 
rate at these sites relative to all other sites, of the same mutational type, in the 
respective genes are given in Table 4. For two of these sites the mutation 
rates are only modestly above background levels; this reflects the power that 
we have to detect significantly hyper-mutable sites in CpG transition sites 
because we have more data than in other mutational categories. However, in 
MECP2 we estimate that site 423, the site which has been hit by 6 non-CpG 
transversion DNMs has a mutation rate at least 150x (or 56x in the restricted 
dataset) higher than the background rate of non-CpG transversion in this 
gene. There is no obvious context effect associated with these sites (Table 4). 
 
Quantification 
The estimates of the mutation rate at different sites are crude; one would 
expect that as more data accumulate so more sites will be found to be 
significantly hyper-mutable and hence the estimates of the rates will increase 
as sites are excluded from the background level. Therefore to better quantify 
the variation in the mutation rate we used maximum likelihood to fit a model in 
which mutation rates were distributed according to a gamma distribution. We 
fit several models in which the distribution of rates (i) was shared across all 
genes and mutational categories, (ii) in which it was shared across genes, (iii) 
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across mutational categories and (iv) finally a model in which every gene and 
mutational category combination had its own distribution. Using likelihood 
ratio tests we find the best supported model is one in which the gamma 
distribution is specific to a mutational category but is shared across genes 
(Table S4).  
 
If we consider the shape parameter estimates for each mutational category it 
seems that CpG transitions have a much lower level of variation than the 
other mutational categories (the higher the values of the shape parameter the 
lower the level of variation) (Table 5). In contrast the other three categories 
show substantial variation. To quantify this variation we calculated the ratio of 
the rates from the 90th and 10th percentiles. Whereas CpG transitions show 
just 1.4 fold variation between the deciles the ratio for all the other categories 
is very substantial; for non-CpG transitions there is 36-fold variation but CpG 
transversions and non-CpG transversions we infer more than a 1000-fold 
variation. However, the confidence intervals on these individual estimates are 
large and are also compatible with modest levels of heterogeneity; this is due 
a lack of data. We therefore combined data from CpG transversions, non-CpG 
transitions and non-CpG transversions. Our estimate of the shape parameter 
is 0.39 (0.21, 0.85) and this corresponds to a ratio of deciles of 550 (i.e. the 
top 10% of sites mutate at least 550x faster than the bottom 10% of sites) with 
95% CIs of 32x, 56,000x. In other words there appears to be very substantial 
variation in the mutation rate within each mutational category, with the 
exception of CpG transitions. 
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Discussion 
We have provided evidence for two types of mutational heterogeneity. First, 
we have demonstrated that there is substantial variation in the relative rates of 
CpG and non-CpG mutations. The most conspicuous pattern is the very high 
rate of CpG transitions relative to non-CpG transversions. Whereas on 
average CpG dinucleotides undergo transition mutations between 18-30 fold 
the rate of non-CpG transversions, in our three Mendelian disease genes they 
undergo 90 to more than 200-fold higher rates of mutation. It is not possible to 
infer whether this is due to a low rate of non-CpG transversion or a high rate 
of CpG transition. Second, we have shown that there is significant 
heterogeneity in the mutation rate between sites within each mutational 
category. This is particularly evident for all categories other than CpG 
transitions; we estimate amongst the other categories that the mutation rate 
may vary by 100-fold or more. 
 
Our conclusions are conditional on the assumption that all the mutations, 
which we have considered, both those that have occurred and those that 
could occur in a gene, are equally likely to be sampled. Variation in sampling 
might arise through three processes – variation in penetrance, alternative 
splicing and ascertainment bias.  
 
In an attempt to ensure that all mutation were equally penetrant we restricted 
our analysis to nonsense mutations, and in the case of RB1 and NF1, to 
nonsense mutations that are predicted to be caught by NMD. In the case of 
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MECP2 most sites that could cause a nonsense mutation are found in the last 
exon and hence would not be caught by NMD. To mitigate against this, we 
have analysed the pattern of mutation both amongst all DNMs and amongst a 
subset of DNMs between the first and last recurrently hit sites. We have found 
similar patterns. If we remove MECP2 from our analysis we still find evidence 
that the ratio of CpG to non-CpG mutations varies between the two disease 
genes and the background rate, and there is still significant heterogeneity in 
the mutation rate within a mutational category (Table 3). Never-the-less it is 
difficult to completely rule-out variation in the level of penetrance as an 
explanation for our results; if the variation in the density of DNMs is due to 
variation in penetrance then our results suggest that penetrance varies 
considerably between mutational categories and between sites within a gene. 
 
The apparent variation in the mutation rate could also be due to 
ascertainment bias. Although we restricted our analysis to data that had come 
from studies in which the same part of the gene had been analysed it is 
possible that the causative mutation was not ascertained and these cases 
discarded. If some mutations are more likely to escape detection than others 
then it will appear as though there is mutation rate variation. 
 
The variation could also potentially be due to alternative splicing (or 
alternative translation start sites) since nonsense mutations in constitutive 
exons might be more penetrant (or more lethal) than nonsense mutations in 
alternatively spliced exons. However, this seems an unlikely explanation for 
our results. RB1 is known to have an alternative translation start site 
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{Sanchez-Sanchez, 2007 #1372} and as a consequence this exon was 
removed from the analysis. There are two major splice forms of MECP2 which 
differ in both their translation start site and the inclusion of exon 2 – variant 1 
includes exon 2, in which translation starts, whereas variant 2 excludes exon 
2 with translation starting in exon 1 {Kriaucionis, 2004 #1370}. We have 
analysed data mapped to variant 1, which differs from variant 2 in the first 26 
bp, so the variation we observe is unlikely to be a consequence of alternative 
splicing associated with the major splice variants in this gene; as such the 
vast majority of the data we have analysed comes from exons that are found 
in the major splice forms. There are multiple splice forms of NF1, although 
most of them yield products that are removed by NMD or result in highly 
truncated proteins {Barron, 2012 #1371}. We have used data that maps to 
transcript variant 2, which is one of two major splice forms. This differs from 
variant 1 in missing exon 23a, a 21 amino acid exon, found in variant 1. So 
again it seems unlikely that alternative splicing can be responsible for our 
results because we have analysed data only from the the exons present in 
both of the two major splice forms. 
 
Another potential explanation for our results is positive selection in the germ-
line. It has been found that some pathogenic mutations are advantageous 
within the male germ-line leading to an increased prevalence of diseases 
such as Apert’s syndrome, which is caused by mutations in the gene FGFR2 
(Goriely and Wilkie, 2012). None of the genes that we have studied are known 
to have mutations that are positively selected in the germ-line and it seems 
unlikely that the heterogeneity amongst nonsense sites could be caused by 
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this process, since all nonsense mutations are predicted to have the same or 
similar phenotypes. 
 
The variation in the density of DNMs is therefore most likely due to variation in 
the mutation rate. It has previously been shown that mutation rates vary at a 
regional scale (reviewed in (Hodgkinson and Eyre-Walker, 2011)). However, it 
has not been noted before that the relative rates of CpG and non-CpG 
mutation can vary substantially. The magnitude of the variation that we have 
observed might in part be due to the fact that genes with the highest mutation 
rates are those most likely to be associated with disease, assuming that the 
high CpG to non-CpG mutation rate reflects a high CpG mutation rate and not 
a low non-CpG rate. There is some evidence for this effect; a recent model of 
the mutation rate at sites in the human genome, based on the analyses of 
DNMs and where they occur, predicts that disease genes have higher rates of 
mutation than non-disease genes (Michaelson, et al., 2012).  
 
It has also been noted that the mutation rate can vary within a mutational 
category because of context (Hodgkinson and Eyre-Walker, 2011) however 
the effects within CpG or non-CpG categories have been inferred to be quite 
modest. For example, Hwang and Green (Hwang and Green, 2004) estimated, 
using the divergence between primate species, that on average CCG, ACG, 
GCG and TCG mutate 24, 29, 18 and 23-fold faster than the genomic average. 
Context effects at non-CpG sites are also fairly modest, typically showing 2-3 
fold variation when the immediately adjacent nucleotides are considered 
(Hwang and Green, 2004), getting progressively weaker as sites further away 
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from the focal site are considered (Zhao and Boerwinkle, 2002). The level of 
variation within all mutational categories except CpG transitions seems to be 
considerably greater than this. The substantial variation in the mutation rate 
within each mutational category, except CpG transitions, is consistent with the 
cryptic variation in the mutation rate, which was first identified in nuclear DNA 
from the coincidence of SNPs in humans and chimpanzees (Hodgkinson, et 
al., 2009; Johnson and Hellmann, 2011). As we have found here, Hodgkinson 
et al. (Hodgkinson, et al., 2009) estimated that there was more variation in the 
mutation rate within non-CpG sites, than within CpG-sites, and estimated that 
a gamma distribution with a shape parameter of 0.85 (0.83, 0.87) fitted the 
data at non-CpG sites. This is not significantly different to the estimate 
obtained here, 0.39 (0.20, 0.91). 
 
The variation at CpG sites could potentially be a consequence of variation in 
methylation. Methylated CpGs are expected to mutate faster than non-
methylated CpGs due to the instability of methyl-cytosine (Coulondre et al. 
1978, Bird. 1980, Sved and Bird. 1990). None of the sequences that we have 
analysed contain CpG islands, regions of the genome in which CpGs are not 
methylated. However, some of the variation may be due to residual variation 
in methylation. 
 
In summary we have shown that there is significant variation in the mutation 
rate both between and within genes. Some of this variation might explain why 
these genes are associated with disease; they have high mutation rates, 
either overall or at specfic sites that can cause disease, and this makes it 
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more likely that pathogenic mutations will recurr in the human population and 
cause disease. 
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 CpG ts CpG tv non-CpG ts non-CpG tv 
RB1 97 5 15 32 
NF1 52 4 24 20 
MECP2 253 0 6 12 
MECP2 – 
restricted 
252 0 2 10 
Kong 855 73 2489 1516 
Michaelson 70 10 282 185 
 
Table 1. The numbers of nonsense DNMs in each gene and mutational 
category for three disease genes. The MECP2 – restricted figures are for 
DNMs between positions 421 and 888. The Kong and Michaelson data are all 
the DNMs reported in Kong et al. (2012) and Michaelson et al. (2012) 
respectively. 
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 CpG ts CpG tv non-CpG ts non-CpG tv 
RB1 90 5.7 3.5 1.0 
NF1 120 14 5.5 1.0 
MECP2 640 0 4.8 1.0 
MECP2 – 
restricted 
240 0 1.5 1.0 
Kong 28 2.4 1.6 1.0 
Michaelson 19 2.7 1.5 1.0 
 
Table 2. The rates of mutation expressed relative to the rate of transversion at 
non-CpG sites. These are derived by dividing the numbers of DNMs by the 
number of sites (Table S1), and then dividing the rate by the rate for non-CpG 
transversions. 
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 CpG ts CpG tv non-CpG ts non-CpG tv 
RB1 0.9990 0.0629 0.0969 0.0412 
NF1 0.0052 0.0344 0.1312 0.6017 
MECP2 <0.0001 - 0.1281 <0.0001 
MECP2 – 
restricted 
<0.0001 - 0.0997 <0.0001 
     
Overall – 
without MECP2 
0.65 0.0089 0.044 0.15 
Overall (row 
above) 
0.0087 
Overall – 
MECP2 all 
0.032 0.0089 0.020 0.0013 
Overall (row 
above) 
2.0 x 10-6 
Overall – 
MECP2 
restricted 
0.032 0.0089 0.016 0.0013 
Overall (row 
above) 
1.6 x 10-6 
 
Table 3. The probability of observing the data under the null hypothesis that 
sites are equally mutable. Probabilities were combined using the unweighted 
Z-method (Whitlock 2005). The data from individual genes are combined in a 
number of different combinations – with and without the MECP2 data, and 
with the restricted MECP2 data. The probabilities are combined for each 
mutational type, but also across genes and mutational types. 
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Gene Mutation 
type 
Rate Context HG19 
coordinates 
MECP2 CpG ts 2.0 
(1.5) 
CCCCTCCCGGCGAGAGCAGAA 
chrX:153,296,777 
MECP2 non-CpG tv 150 
(56) 
TGATTGCGTACTTCGAAAAGG 
chrX:153,296,856 
NF1 CpG ts 4.0 TGTTGGAAGACGACCTTTTGA chr17:29,588,751 
 
Table 4. Significantly hypermutable sites. Numbers in parentheses in the rate 
column are estimates from the restricted MECP2 data. The nucleotide 
underlined in the context column is the hypermutable site. 
 
 
  
 30 
 
Mutation type Shape Ratio of the rates of first 
and last deciles 
cts 63 (13, infinity) 1.4 (2.1, 1.0) 
ctv 0.39 (0.069, infinity) 550 (7.7 x 1013, 1.0) 
nts 0.81 (0.26, infinity) 36 (8000, 1.0) 
ntv 0.24 (0.11, 0.64) 16,000 (6.1 x 1014, 70) 
ctv+ntv 0.26 (0.13, 0.64) 8000 (3.0 x 107, 70) 
nts+ntv 0.39 (0.20, 0.91) 550 (93,000, 27) 
ctv+nts+ntv 0.39 (0.21, 0.85) 550 (56,000, 32) 
 
Table 5. Estimates of the shape parameter of the gamma distribution and the 
ratio of the upper and lower deciles of the distribution. 95% confidence 
intervals, as inferred from the likelihood surface, are given in brackets. 
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Figure 1. The distribution of nonsense DNMs and sites at which a mutation 
can cause a nonsense mutation in the MECP2 gene. The start of the last 
exon is marked.  
